Navigation Links
Schizophrenia genetic networks identified; Connection to autism found
Date:11/11/2012

alysis uncovers genetic networks

To discover potential connections among genes mutated in schizophrenia, Dr. Vitkup and colleagues developed a computational approach, called NETBAG+, to identify networks of genes likely to be responsible for the same genetic phenotype. They then gathered the strongest mutations that had been observed in schizophrenia by other researchersincluding a set of de novo mutations recently described by a team of Columbia researchers led by Maria Karayiorgou, MD, and Joseph A. Gogos, MD, PhDand fed them into the program.

The program uncovered two genetic networks. Genes in the first network are involved primarily in axon guidance, synapse function, and cell migration. Genes in the second network are involved in chromosomal organization and remodeling.

Parts of both networks are highly active during prenatal development, suggesting that changes in the brain that cause schizophrenia later in life are laid down very early in life.

Connection to autism

Dr. Vitkup also compared his schizophrenia networks with networks found in neurodevelopmental disorders such as autism. One schizophrenia network is strongly related to an autism network he described in a study published last year. Both networks contain genes involved in axon guidance, synapse function, and cell migration.

"Our recent mutational analysis showed that this overlap includes primarily genes that are important for early fetal development. This is not surprising, because some cases of schizophrenia and likely many cases of autism have neurodevelopmental origin," said Dr. Karayiorgou.

The close relationship between genetic networks involved in autism and schizophrenia raises an intriguing question: How can mutations in the same or related genes cause two different disorders?

"I like to use the analogy of car brakes," said Dr. Vitkup. "Different mechanical malfunctions of the brake mechanism can have very d
'/>"/>

Contact: Karin Eskenazi
ket2116@columbia.edu
212-342-0508
Columbia University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Cannabis use mimics cognitive weakness that can lead to schizophrenia
2. Inflammation and cognition in schizophrenia
3. Researchers pursue red flag for schizophrenia relapse
4. Johns Hopkins researchers link 2 biological risk factors for schizophrenia
5. The music of the (hemi)spheres sheds new light on schizophrenia
6. Weber State Scientists discover possible building blocks of ancient genetic systems
7. Texas cotton getting a genetic tune-up
8. Renewal grant supports genetic research into arthritis of the spine
9. Verinata Health Announces New Findings At The American Society Of Human Genetics
10. Autism Speaks announces the release of new genetic data for researchers
11. Genetics Society of Americas GENETICS journal highlights for November 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... than 200 million years ago, a massive extinction decimated ... end of the Triassic period and the onset of ... dinosaurs to dominate Earth for the next 135 million ... marine and terrestrial species. It,s not entirely clear ...
... gentler chemotherapy drug in the form of nanoparticles has been designed ... woman,s fertility but extra tough on cancer. This is the first ... using a novel in vitro test. ... that predicts the toxicity of a chemotherapy drug to fertility and ...
... WASHINGTON, D.C.--Pit latrines are one of the most common ... on the rise as countries aim to meet the ... evidence supports the use of these basic toilets as ... pit latrines can actually allow disease-causing microbes or other ...
Cached Biology News:Huge and widespread volcanic eruptions triggered the end-Triassic extinction 2Huge and widespread volcanic eruptions triggered the end-Triassic extinction 3Huge and widespread volcanic eruptions triggered the end-Triassic extinction 4New chemo drug gentler on fertility, tougher on cancer 2New chemo drug gentler on fertility, tougher on cancer 3Additional research must be done to ensure safety of pit latrines, new study says 2
(Date:7/30/2015)... DALLAS , July 30, 2015  With over 60,000 customers across the globe, ISN ... helps connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 ... ... ... Headquartered in Dallas, ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... WARSAW, Ind., Sept. 15 Symmetry Medical Inc.,(NYSE: ... the global,orthopedic device industry and other medical markets, announced ... is scheduled to,present at the UBS Global Life Sciences ... City on Thursday, September 25, 2008 at 11:30 a.m. ...
... Corporation,(OTC Bulletin Board: CONX), a worldwide developer and ... call on Thursday, September,25, 2008, at 4:00 PM ... for its fiscal year ended June 30, 2008, ... marketing activities., Corgenix invites all those interested ...
... 15 Epeius Biotechnologies,Corporation today announced that Rexin-G, ... been highlighted in a recent NEWS article,published by ... Sept. 9,2008). The article, authored by Vickie Brower, ... that may succeed where small,molecules and proteins have ...
Cached Biology Technology:Symmetry Medical to Present at UBS Global Life Sciences Conference 2Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
Biology Products: